Neutropenia while receiving anti-tumour necrosis factor treatment for rheumatoid arthritis [11]

Annals of the Rheumatic Diseases

Volumn 65, Issue 12, 2006, Pages 1678-1679

  Rajakulendran, S ^a   Gadsby, K ^a   Allen, D ^a   O'Reilly, S ^a   Deighton, C ^a  

^a DERBYSHIRE ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ETANERCEPT; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE;

BLOOD CELL COUNT; HUMAN; LETTER; NEUTROPENIA; NEUTROPHIL; NEUTROPHIL COUNT; PRACTICE GUIDELINE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL RESPONSE MODIFIERS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUTROPENIA; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33751270224     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2006.056176     Document Type: Letter

References (8)

1. Ledingham J, Deighton C. Update on the British Society of Rheumatology guidelines for prescribing TNFα blockers in adults with rheumatoid arthritis (update of previous guidelines of April 2001). Rheumatology 2005;44:157-63.
2. Furst DE, Breedveld FC, Kalden JR, Burmester GR, Smolen JS, Bijlsma JWJ, et al. Updated consensus on biological agents, specifically tumour necrosis factor α, (TNFα) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases. Ann Rheum Dis 2005;64:iv2-14.
3. Markham A, Lamb HM. Infliximab: a review of its use in the management of rheumatoid arthritis. Drugs 2000;59:1341-59.
4. Jarvis B, Faulds D. Etanercept: a review of its use in rheumatoid arthritis. Drugs 1999;57:945-66.
5. Vidal F, Fontova R, Richart C. Severe neutropaenia and thrombocytopaenia associated with infliximab. Ann Intern Med 2003;139:63.
6. Maini RN, Breedveld FC, Kalden JR, Smolen JS, Davis D, MacFarlane JD, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumour necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998;41:1552-63.
7. Kuruvilla J, Leitch HA, Vickars LM, Galbraith PF, Li CH, Al-Saab S, et al. Aplastic anaemia following administration of a tumour necrosis factor-alpha inhibitor. Eur J Haematol 2003;71:396-8.
8. Rajakulendran S, Allen D, Deighton C. Should the monitoring of methotrexate and leflunomide be the same? Rheumatology 2005;44(Suppl 1):i65.